肿瘤细胞治疗研究
英文原题：Current salvage therapies in Hodgkin lymphoma.
Current salvage therapies in Hodgkin lymphoma.
霍奇金淋巴瘤是一种 B 细胞恶性肿瘤，一线治疗后的完全缓解率约为 85-95%；然而，治疗后约 10-30% 的患者会出现复发/难治性疾病。
霍奇金淋巴瘤是一种B细胞恶性肿瘤，一线治疗后的完全缓解率约为85%至95%；然而，治疗后约10%至30%的患者会出现复发/难治性疾病。传统挽救治疗主要依靠细胞毒性化疗，随后进行大剂量化疗和自体干细胞移植。相当一部分患者移植后仍复发，后续挽救治疗包括异基因移植和放疗。过去十年中，brentuximab vedotin、PD-1抑制剂等新疗法以及PET影像纳入治疗决策，改变了复发/难治性疾病的治疗模式。新疗法已在单药方案及与其他新型疗法或传统化疗的联合方案中开展研究。CD30.CAR-T细胞疗法、AFM13、camidanlumab tesirine、新型PD-1抑制剂以及JAK1/JAK2抑制剂在治疗中的早期研究结果令人鼓舞。本文综述霍奇金淋巴瘤当前的挽救治疗和复发/难治性疾病管理的未来方向。
Hodgkin lymphoma is a B-cell malignancy with approximately 85-95% complete remission rate following frontline therapy; however, relapsed/refractory disease occurs in roughly 10-30% of patients after treatment. Salvage therapy conventionally relies upon cytotoxic chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation. A considerable number of patients experience relapse after transplantation, and further salvage management has included the use of allogeneic transplantation and radiotherapy. In the past decade, novel therapies including, brentuximab vedotin, PD-1 inhibitors, and the incorporation of PET-imaging into management have changed the paradigm of relapsed/refractory disease care. Novel therapies have been investigated in both single and combination regimens with other novel therapies and traditional chemotherapies. There is promising early work into the utility of CD30.CAR-T cell therapy, AFM13, camidanlumab tesirine, novel PD-1 inhibitors, and JAK1/JAK2 inhibition in management. Herein, we will review current salvage therapies in Hodgkin lymphoma and future directions in relapsed/refractory disease management.
MEMBER ACCOUNT
登录成功会直接打开下一页。
